Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Friday's Featured Story Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we’re still in one of the best times in history to build wealth—especially if you think long term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling pressure has more to do with valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back See Early-Stage Activity Before It Reaches Mainstream Screens
We highlight micro-cap and small-cap companies gaining early traction based on research, visibility shifts, and market interest. Get the Free Guide — Join Now Green attributes the dip to two core concerns. First, investors are questioning elevated tech and AI valuations, particularly as earnings season brings those expectations into focus. Second, inflation data and slower hiring have dampened hopes that the Fed will cut rates in December. With the central bank taking a "data-dependent" stance, markets are less certain that relief is coming this year. Why Selling Now Might Be the Wrong Move Rather than trying to predict next week’s moves, Green urges investors to zoom out. He calls himself "a long-term optimist" and points out that, historically, the market's trend is upward. Short-term traders may want to be cautious. For long-term investors, however, these dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable indicator in times like these is insider buying. Green says when officers and directors—people with access to non-public financials—are putting their own money into their companies, it’s worth noting. He recommends tracking insider trading activity to see which stocks corporate executives are buying, not just selling. While insiders aren't always right, their actions can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green has used the test himself and calls it "a good feeling" to know you’re clear of so many deadly diseases—especially cancers like pancreatic that often go undetected until late stages. With FDA fast-track status and potential insurance reimbursement ahead, Green sees GRAIL's roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Of course, biotech carries risk. Most drugs never make it through all phases of trials. Still, large pharmaceutical companies such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as an example: the company invested in a private firm developing a prostate cancer drug before it received FDA approval—underscoring how aggressive Big Pharma can be when clinical trials look promising. He also believes biotech is especially compelling now because healthcare is largely recession-resistant. Whether the economy is expanding or contracting, people still seek treatment. For investors looking to weather volatility, sectors like healthcare, utilities, consumer staples, and food companies tend to offer steady demand—and less drama than some high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream is far from dead. He wrote The American Dream to counter the narrative that it's out of reach, noting his surprise that nearly 70% of Americans believe it's no longer attainable. The reality, he says, is that with low-cost investment tools, no-commission trading, and abundant information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to follow through. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save and leave the money to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says it doesn't have to be. Mortgage rates have doubled and prices are up roughly 50% since the pandemic—but there are still ways to get in. He shares his personal story of buying two houses with no money down by working with motivated sellers and assuming their mortgages—a method often structured as a "contract for deed." It might not land you a perfect house right away, but it can help you start building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside areas like biotech, or simply believing in your ability to build a financial future, Green's message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
